DURECT Corporation (DRRX)
USD 0.69
(-1.2%)
USD 0.69
(-1.2%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 30.4 Million USD | -13.41% |
| 2022 | 35.11 Million USD | 2.65% |
| 2021 | 34.2 Million USD | -3.71% |
| 2020 | 35.52 Million USD | -43.75% |
| 2019 | 63.16 Million USD | 110.54% |
| 2018 | 29.99 Million USD | -5.14% |
| 2017 | 31.62 Million USD | -1.69% |
| 2016 | 32.17 Million USD | 0.88% |
| 2015 | 31.88 Million USD | 1.01% |
| 2014 | 31.56 Million USD | 212.6% |
| 2013 | 10.09 Million USD | 5.15% |
| 2012 | 9.6 Million USD | -78.99% |
| 2011 | 45.71 Million USD | -13.86% |
| 2010 | 53.07 Million USD | 72.68% |
| 2009 | 30.73 Million USD | -20.08% |
| 2008 | 38.45 Million USD | -22.22% |
| 2007 | 49.43 Million USD | -24.47% |
| 2006 | 65.45 Million USD | -11.62% |
| 2005 | 74.06 Million USD | 10.41% |
| 2004 | 67.07 Million USD | -0.32% |
| 2003 | 67.29 Million USD | 891.19% |
| 2002 | 6.78 Million USD | -14.01% |
| 2001 | 7.89 Million USD | 47.35% |
| 2000 | 5.35 Million USD | 208.82% |
| 1999 | 1.73 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 24.81 Million USD | -11.12% |
| 2024 Q1 | 27.92 Million USD | -8.17% |
| 2023 Q2 | 43.15 Million USD | 0.35% |
| 2023 Q1 | 43 Million USD | 22.47% |
| 2023 Q4 | 30.4 Million USD | -24.59% |
| 2023 FY | 30.4 Million USD | -13.41% |
| 2023 Q3 | 40.32 Million USD | -6.57% |
| 2022 FY | 35.11 Million USD | 2.65% |
| 2022 Q1 | 32.92 Million USD | -3.75% |
| 2022 Q3 | 33.61 Million USD | 1.03% |
| 2022 Q2 | 33.27 Million USD | 1.07% |
| 2022 Q4 | 35.11 Million USD | 4.45% |
| 2021 Q1 | 34.33 Million USD | -3.36% |
| 2021 FY | 34.2 Million USD | -3.71% |
| 2021 Q4 | 34.2 Million USD | 0.8% |
| 2021 Q2 | 32.8 Million USD | -4.45% |
| 2021 Q3 | 33.93 Million USD | 3.44% |
| 2020 Q3 | 35.45 Million USD | -2.65% |
| 2020 Q1 | 60.04 Million USD | -4.93% |
| 2020 FY | 35.52 Million USD | -43.75% |
| 2020 Q4 | 35.52 Million USD | 0.19% |
| 2020 Q2 | 36.42 Million USD | -39.35% |
| 2019 Q4 | 63.16 Million USD | -4.67% |
| 2019 Q2 | 37.09 Million USD | -0.79% |
| 2019 Q1 | 37.38 Million USD | 24.63% |
| 2019 Q3 | 66.25 Million USD | 78.61% |
| 2019 FY | 63.16 Million USD | 110.54% |
| 2018 Q3 | 30.76 Million USD | 5.62% |
| 2018 FY | 29.99 Million USD | -5.14% |
| 2018 Q1 | 29.28 Million USD | -7.4% |
| 2018 Q2 | 29.12 Million USD | -0.53% |
| 2018 Q4 | 29.99 Million USD | -2.49% |
| 2017 Q2 | 51.77 Million USD | 73.44% |
| 2017 Q1 | 29.85 Million USD | -7.21% |
| 2017 FY | 31.62 Million USD | -1.69% |
| 2017 Q3 | 47.71 Million USD | -7.83% |
| 2017 Q4 | 31.62 Million USD | -33.72% |
| 2016 Q3 | 30.63 Million USD | -2.22% |
| 2016 Q1 | 30.97 Million USD | -2.87% |
| 2016 Q2 | 31.32 Million USD | 1.15% |
| 2016 Q4 | 32.17 Million USD | 5.02% |
| 2016 FY | 32.17 Million USD | 0.88% |
| 2015 Q3 | 31.1 Million USD | 2.93% |
| 2015 Q4 | 31.88 Million USD | 2.54% |
| 2015 FY | 31.88 Million USD | 1.01% |
| 2015 Q1 | 30.04 Million USD | -4.83% |
| 2015 Q2 | 30.21 Million USD | 0.57% |
| 2014 Q1 | 8.32 Million USD | -17.59% |
| 2014 Q2 | 28.37 Million USD | 240.9% |
| 2014 FY | 31.56 Million USD | 212.6% |
| 2014 Q3 | 29.31 Million USD | 3.33% |
| 2014 Q4 | 31.56 Million USD | 7.68% |
| 2013 FY | 10.09 Million USD | 5.15% |
| 2013 Q4 | 10.09 Million USD | 25.36% |
| 2013 Q3 | 8.05 Million USD | 10.01% |
| 2013 Q1 | 7.38 Million USD | -23.16% |
| 2013 Q2 | 7.32 Million USD | -0.77% |
| 2012 Q1 | 7.72 Million USD | -83.09% |
| 2012 Q2 | 7.47 Million USD | -3.31% |
| 2012 FY | 9.6 Million USD | -78.99% |
| 2012 Q4 | 9.6 Million USD | 27.22% |
| 2012 Q3 | 7.54 Million USD | 1.02% |
| 2011 Q3 | 49.13 Million USD | 4.68% |
| 2011 FY | 45.71 Million USD | -13.86% |
| 2011 Q4 | 45.71 Million USD | -6.94% |
| 2011 Q2 | 46.93 Million USD | -4.77% |
| 2011 Q1 | 49.28 Million USD | -7.14% |
| 2010 Q3 | 52.12 Million USD | -3.72% |
| 2010 FY | 53.07 Million USD | 72.68% |
| 2010 Q2 | 54.14 Million USD | 84.71% |
| 2010 Q4 | 53.07 Million USD | 1.81% |
| 2010 Q1 | 29.31 Million USD | -3.29% |
| 2009 Q4 | 30.3 Million USD | -2.24% |
| 2009 FY | 30.73 Million USD | -20.08% |
| 2009 Q1 | 35.94 Million USD | -3.66% |
| 2009 Q2 | 34.25 Million USD | -4.7% |
| 2009 Q3 | 31 Million USD | -9.51% |
| 2008 Q1 | 45.91 Million USD | -7.12% |
| 2008 Q3 | 20.58 Million USD | -6.71% |
| 2008 Q2 | 22.06 Million USD | -51.95% |
| 2008 FY | 38.45 Million USD | -22.22% |
| 2008 Q4 | 37.31 Million USD | 81.27% |
| 2007 Q2 | 64.61 Million USD | -0.92% |
| 2007 FY | 49.43 Million USD | -24.47% |
| 2007 Q4 | 49.43 Million USD | -18.3% |
| 2007 Q1 | 65.21 Million USD | -0.36% |
| 2007 Q3 | 60.51 Million USD | -6.35% |
| 2006 Q4 | 65.45 Million USD | 25.45% |
| 2006 Q3 | 52.17 Million USD | 2.27% |
| 2006 Q2 | 51.01 Million USD | -29.26% |
| 2006 Q1 | 72.12 Million USD | -2.62% |
| 2006 FY | 65.45 Million USD | -11.62% |
| 2005 Q2 | 76.62 Million USD | -1.26% |
| 2005 Q3 | 74.66 Million USD | -2.56% |
| 2005 Q4 | 74.06 Million USD | -0.8% |
| 2005 FY | 74.06 Million USD | 10.41% |
| 2005 Q1 | 77.6 Million USD | 15.7% |
| 2004 Q3 | 68.07 Million USD | 1.33% |
| 2004 Q4 | 67.07 Million USD | -1.46% |
| 2004 FY | 67.07 Million USD | -0.32% |
| 2004 Q1 | 67.89 Million USD | 0.9% |
| 2004 Q2 | 67.17 Million USD | -1.06% |
| 2003 Q1 | 7.07 Million USD | 4.21% |
| 2003 FY | 67.29 Million USD | 891.19% |
| 2003 Q2 | 57.03 Million USD | 706.09% |
| 2003 Q3 | 68.86 Million USD | 20.74% |
| 2003 Q4 | 67.29 Million USD | -2.28% |
| 2002 Q3 | 7.6 Million USD | 12.91% |
| 2002 Q4 | 6.78 Million USD | -10.75% |
| 2002 Q1 | 7.37 Million USD | -6.61% |
| 2002 Q2 | 6.73 Million USD | -8.63% |
| 2002 FY | 6.78 Million USD | -14.01% |
| 2001 FY | 7.89 Million USD | 47.35% |
| 2001 Q4 | 7.89 Million USD | -13.83% |
| 2001 Q3 | 9.16 Million USD | 12.94% |
| 2001 Q2 | 8.11 Million USD | 28.6% |
| 2001 Q1 | 6.3 Million USD | 17.73% |
| 2000 FY | 5.35 Million USD | 208.82% |
| 2000 Q3 | 4.53 Million USD | -15.97% |
| 2000 Q4 | 5.35 Million USD | 18.23% |
| 2000 Q2 | 5.39 Million USD | 0.0% |
| 1999 FY | 1.73 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Intra-Cellular Therapies, Inc. | 136.87 Million USD | 77.785% |
| PainReform Ltd. | 2.69 Million USD | -1029.915% |
| Alvotech | 1.88 Billion USD | 98.385% |
| Collegium Pharmaceutical, Inc. | 947.87 Million USD | 96.792% |
| ANI Pharmaceuticals, Inc. | 471.67 Million USD | 93.554% |
| Aquestive Therapeutics, Inc. | 163.9 Million USD | 81.449% |
| Journey Medical Corporation | 56.49 Million USD | 46.183% |
| Dynavax Technologies Corporation | 375.02 Million USD | 91.892% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | 95.399% |
| Bright Green Corporation | 6.43 Million USD | -372.282% |
| Pacira BioSciences, Inc. | 704.25 Million USD | 95.683% |
| Embecta Corp. | 2.03 Billion USD | 98.507% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -395.244% |
| Sunshine Biopharma, Inc. | 6.13 Million USD | -395.244% |
| SCYNEXIS, Inc. | 55.45 Million USD | 45.165% |
| Petros Pharmaceuticals, Inc. | 21.31 Million USD | -42.646% |
| Silver Spike Investment Corp. | 3 Million USD | -910.223% |
| China SXT Pharmaceuticals, Inc. | 9.19 Million USD | -230.622% |
| Alpha Teknova, Inc. | 38.55 Million USD | 21.128% |
| Safety Shot Inc | 3.89 Million USD | -681.235% |
| Procaps Group, S.A. | 462.06 Million USD | 93.42% |
| Cosmos Health Inc. | 30.25 Million USD | -0.507% |
| Theratechnologies Inc. | 98.63 Million USD | 69.174% |
| Harrow Health, Inc. | 241.75 Million USD | 87.423% |
| Sonoma Pharmaceuticals, Inc. | 8.75 Million USD | -247.259% |
| Biofrontera Inc. | 23.13 Million USD | -31.406% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | 93.762% |
| Cronos Group Inc. | 43.73 Million USD | 30.478% |
| OptiNose, Inc. | 194.33 Million USD | 84.354% |
| Ironwood Pharmaceuticals, Inc. | 817.36 Million USD | 96.28% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | 37.236% |
| RedHill Biopharma Ltd. | 20.97 Million USD | -44.941% |
| Organogenesis Holdings Inc. | 181.36 Million USD | 83.235% |
| Guardion Health Sciences, Inc. | 3.77 Million USD | -706.069% |
| Cumberland Pharmaceuticals Inc. | 52.51 Million USD | 42.102% |
| Radius Health, Inc. | 804.29 Million USD | 96.22% |
| Universe Pharmaceuticals INC | 13.75 Million USD | -121.065% |
| ProPhase Labs, Inc. | 42.54 Million USD | 28.53% |
| Phibro Animal Health Corporation | 725.54 Million USD | 95.809% |
| Procaps Group S.A. | 462.06 Million USD | 93.42% |
| TherapeuticsMD, Inc. | 14.02 Million USD | -116.845% |
| Viatris Inc. | 27.21 Billion USD | 99.888% |
| Rockwell Medical, Inc. | 30.88 Million USD | 1.541% |
| Aytu BioPharma, Inc. | 90.37 Million USD | 66.357% |
| SIGA Technologies, Inc. | 57.97 Million USD | 47.555% |
| Tilray Brands, Inc. | 892.11 Million USD | 96.592% |
| Lifecore Biomedical, Inc. | 219.8 Million USD | 86.167% |
| Shineco, Inc. | 47.6 Million USD | 36.124% |
| PetIQ, Inc. | 645.22 Million USD | 95.288% |
| Regencell Bioscience Holdings Limited | 219.51 Thousand USD | -13751.635% |
| Incannex Healthcare Limited | 5.83 Million USD | -421.544% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | 97.017% |
| Alimera Sciences, Inc. | 107.35 Million USD | 71.677% |
| Assertio Holdings, Inc. | 148.41 Million USD | 79.513% |
| Shuttle Pharmaceuticals Holdings, Inc. | 1.89 Million USD | -1503.722% |
| Clever Leaves Holdings Inc. | 7.02 Million USD | -332.764% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -258.117% |
| Avadel Pharmaceuticals plc | 173.38 Million USD | 82.464% |
| Hempacco Co., Inc. | 18.82 Million USD | -61.542% |
| Talphera, Inc. | 6.29 Million USD | -383.402% |
| Alvotech | 1.88 Billion USD | 98.385% |
| Eagle Pharmaceuticals, Inc. | 172.6 Million USD | 82.384% |
| Lantheus Holdings, Inc. | 835.25 Million USD | 96.36% |
| Currenc Group, Inc. | 177.67 Million USD | 82.887% |
| Kamada Ltd. | 109.96 Million USD | 72.35% |
| Indivior PLC | 1.95 Billion USD | 98.442% |
| Evoke Pharma, Inc. | 9.64 Million USD | -215.151% |
| Flora Growth Corp. | 17.22 Million USD | -76.553% |
| Cyclo Therapeutics, Inc. | 8.49 Million USD | -258.117% |
| Evolus, Inc. | 209.68 Million USD | 85.499% |
| HUTCHMED (China) Limited | 536.38 Million USD | 94.331% |
| Amphastar Pharmaceuticals, Inc. | 873.49 Million USD | 96.519% |
| Akanda Corp. | 12.66 Million USD | -140.005% |